Boron/Nitrogen-Doped Carbon Nano-Onions as Nanocarriers for Targeted Breast Cancer Therapy

    January 2025 in “ Nanoscale ”
    Hugh Mohan, Iris C. Salaroglio, Michał Bartkowski, Kevin D. Courtney, Ilaria Andreana, Tania Limongi, Raúl Arenal, Chiara Riganti, Silvia Arpicco, Silvia Giordani
    TLDR Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
    This study investigates boron/nitrogen-doped carbon nano-onions (BN-CNOs) as nanocarriers for targeted breast cancer therapy, specifically for triple-negative breast cancer (TNBC). The nanocarriers, functionalized with a hyaluronic acid/phospholipid conjugate (HA-DMPE), enhance the delivery of doxorubicin (DOX) to cancer cells, leveraging a pH-dependent release mechanism. The 20/100/120 wt% HA-DMPE/BN-CNO/DOX formulation achieved an 84% drug release efficiency and significantly improved DOX uptake and anticancer efficacy in CD44-expressing TNBC cell lines, reducing cell viability to 9% in MDA-MB-231 cells at 120 hours. This approach offers a promising alternative to current DOX treatments, with increased efficacy, stability, and reduced cardiotoxicity.
    Discuss this study in the Community →